Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.40 |
| ▸ | PTPRA | P18433 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5292853 | 0.80 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| SCHEMBL26912795 | 0.80 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| SCHEMBL1539194 | 0.80 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| Hydrochloric Acid SCHEMBL28353144 | 0.78 | SLC7A5 (0.51) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| SCHEMBL13095827 | 0.78 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| SCHEMBL4854900 | 0.78 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| SCHEMBL59810 | 0.78 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| SCHEMBL59078 | 0.78 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| SCHEMBL5289317 | 0.78 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 | |
| SCHEMBL5279998 | 0.76 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3GRIA2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035952-A1 | Radiosensitizer Formulations and Methods for Use | Matthews, Dr. Richard H. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7608612-B2 | Radiosensitizer formulations and methods for use | Matthews, Richard H. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1838305-A1 | RADIOSENSITIZER FORMULATIONS COMPRISING NITROHISTIDINE DERIVATIVES | Matthews, Richard H. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060193917-A1 | Radiosensitizer formulations and methods for use | MATTHEWS, RICHARD H., DR. | 2006-08-31 | — | — | US | disclosed |
| WO-2006078903-A1 | RADIOSENSITIZER FORMULATIONS COMPRISING NITROHISTIDINE DERIVATIVES | MATTHEWS RICHARD H (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035952-A1 | Radiosensitizer Formulations and Methods for Use | NOS2, IDH1, HNMT | SLC7A5 189/4885CYP3A4 1580/4885SLC1A3 668/4885 |
| US-20060193917-A1 | Radiosensitizer formulations and methods for use | NOS2, IDH1, HNMT | SLC7A5 189/4885CYP3A4 1580/4885SLC1A3 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.